SCHEMBL5756506

SCHEMBL5756506

CCCCCCCSc1nc2ccc(S(=O)(=O)N[C@H](Cc3ccc(OCCCN4C(=O)c5ccccc5C4=O)cc3)C(=O)NO)cc2s1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 3/20 0.44
MMP2 P08253 3/20 0.44
MMP9 P14780 3/20 0.44
MMP14 P50281 3/20 0.44
ADAM17 P78536 2/20 0.44
ADAM10 O14672 1/20 0.44
RXFP1 Q9HBX9 3/20 0.41
LDHA P00338 1/20 0.40
MAPT P10636 8/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
MMP25 Q9NPA2 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ALDH1A1 P00352 1/20 0.38
THRB P10828 2/20 0.38
PPARA Q07869 2/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756033 0.94 LDHA (0.43) RXFP1LDHAMAPTMMP3LMNA
SCHEMBL5757436 0.88 MMP2 (0.47) MMP1MMP2MMP9MMP14RXFP1
SCHEMBL5754752 0.88 MMP2 (0.49) MMP1MMP2MMP9MMP14RXFP1
SCHEMBL5755029 0.87 MMP2 (0.52) MMP1MMP2MMP9MMP14ADAM17
SCHEMBL5754992 0.85 MMP2 (0.49) MMP2MMP9MMP14RXFP1MAPT
SCHEMBL5757499 0.84 MMP2 (0.50) MMP1MMP2MMP9MMP14RXFP1
SCHEMBL5754585 0.84 MMP9 (0.41) MMP1MMP2MMP9MMP14ADAM17
SCHEMBL5756234 0.84 LDHA (0.40) MMP1MMP2MMP9MMP14RXFP1
SCHEMBL6975991 0.84 MMP9 (0.41) MMP1MMP2MMP9MMP14ADAM17
SCHEMBL6976625 0.83 ALDH1A1 (0.38) MMP1MMP2MMP9MMP14ADAM17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP1 6/4885MMP2 8/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.